Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Filter bei nächster Suche beibehalten
collection:"CTG"
topic_facet:"Medical Condition: Hypersensitivity reaction (HSR) is a common toxicity associated with oxaliplatin. Oxaliplatin is a chemotherapy mainly used in gastrointestinal malignancies especially colorectal cancer. The incidences of oxaliplatin induced HSR vary from 12% to 25% (1-5) (6-8) (9, 10). Although it is usually mild to moderate severity (11), it could be severe (9, 10) and result in treatment discontinuation. Oxaliplatin induced HSR is a type I hypersensitivity. It usually occurs in later cycles of treatment course. In a common oxaliplatin based regimen, FOLFOX, it is more likely to firstly occur in seventh to ninth cycle of twelve-cycle treatment course.(12). Although many studies identified risk factors for HSRs, the most consistent risk factor is the number of oxaliplatin administered. (13-15) To date, there have been a few studies exploring preventive strategies for oxaliplatin induced HSRs. Most of them were retrospective or single-arm prospective studies. In this study, we conducted a randomization controlled trial to explore the efficacy of additional antihistamine premedication and infusion prolongation in prevention of oxaliplatin induced HSRs. Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention;Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention"
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Hypersensitivity+reaction+%28HSR%29+is+a+common+toxicity+associated+with+oxaliplatin.+Oxaliplatin+is+a+chemotherapy+mainly+used+in+gastrointestinal+malignancies+especially+colorectal+cancer.+The+incidences+of+oxaliplatin+induced+HSR+vary+from+12%25+to+25%25+%281-5%29+%286-8%29+%289%2C+10%29.+Although+it+is+usually+mild+to+moderate+severity+%2811%29%2C+it+could+be+severe+%289%2C+10%29+and+result+in+treatment+discontinuation.+Oxaliplatin+induced+HSR+is+a+type+I+hypersensitivity.+It+usually+occurs+in+later+cycles+of+treatment+course.+In+a+common+oxaliplatin+based+regimen%2C+FOLFOX%2C+it+is+more+likely+to+firstly+occur+in+seventh+to+ninth+cycle+of+twelve-cycle+treatment+course.%2812%29.+Although+many+studies+identified+risk+factors+for+HSRs%2C+the+most+consistent+risk+factor+is+the+number+of+oxaliplatin+administered.+%2813-15%29+To+date%2C+there+have+been+a+few+studies+exploring+preventive+strategies+for+oxaliplatin+induced+HSRs.+Most+of+them+were+retrospective+or+single-arm+prospective+studies.+In+this+study%2C+we+conducted+a+randomization+controlled+trial+to+explore+the+efficacy+of+additional+antihistamine+premedication+and+infusion+prolongation+in+prevention+of+oxaliplatin+induced+HSRs.+Oxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%3BOxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%22&lookfor=%22Prospective+Studies%22&type=Subject
/vufind/Search/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Hypersensitivity+reaction+%28HSR%29+is+a+common+toxicity+associated+with+oxaliplatin.+Oxaliplatin+is+a+chemotherapy+mainly+used+in+gastrointestinal+malignancies+especially+colorectal+cancer.+The+incidences+of+oxaliplatin+induced+HSR+vary+from+12%25+to+25%25+%281-5%29+%286-8%29+%289%2C+10%29.+Although+it+is+usually+mild+to+moderate+severity+%2811%29%2C+it+could+be+severe+%289%2C+10%29+and+result+in+treatment+discontinuation.+Oxaliplatin+induced+HSR+is+a+type+I+hypersensitivity.+It+usually+occurs+in+later+cycles+of+treatment+course.+In+a+common+oxaliplatin+based+regimen%2C+FOLFOX%2C+it+is+more+likely+to+firstly+occur+in+seventh+to+ninth+cycle+of+twelve-cycle+treatment+course.%2812%29.+Although+many+studies+identified+risk+factors+for+HSRs%2C+the+most+consistent+risk+factor+is+the+number+of+oxaliplatin+administered.+%2813-15%29+To+date%2C+there+have+been+a+few+studies+exploring+preventive+strategies+for+oxaliplatin+induced+HSRs.+Most+of+them+were+retrospective+or+single-arm+prospective+studies.+In+this+study%2C+we+conducted+a+randomization+controlled+trial+to+explore+the+efficacy+of+additional+antihistamine+premedication+and+infusion+prolongation+in+prevention+of+oxaliplatin+induced+HSRs.+Oxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%3BOxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%22&lookfor=%22Prospective+Studies%22&type=Subject
Search /vufind/Search2/Results?filter%5B%5D=collection%3A%22CTG%22&filter%5B%5D=topic_facet%3A%22Medical+Condition%3A+Hypersensitivity+reaction+%28HSR%29+is+a+common+toxicity+associated+with+oxaliplatin.+Oxaliplatin+is+a+chemotherapy+mainly+used+in+gastrointestinal+malignancies+especially+colorectal+cancer.+The+incidences+of+oxaliplatin+induced+HSR+vary+from+12%25+to+25%25+%281-5%29+%286-8%29+%289%2C+10%29.+Although+it+is+usually+mild+to+moderate+severity+%2811%29%2C+it+could+be+severe+%289%2C+10%29+and+result+in+treatment+discontinuation.+Oxaliplatin+induced+HSR+is+a+type+I+hypersensitivity.+It+usually+occurs+in+later+cycles+of+treatment+course.+In+a+common+oxaliplatin+based+regimen%2C+FOLFOX%2C+it+is+more+likely+to+firstly+occur+in+seventh+to+ninth+cycle+of+twelve-cycle+treatment+course.%2812%29.+Although+many+studies+identified+risk+factors+for+HSRs%2C+the+most+consistent+risk+factor+is+the+number+of+oxaliplatin+administered.+%2813-15%29+To+date%2C+there+have+been+a+few+studies+exploring+preventive+strategies+for+oxaliplatin+induced+HSRs.+Most+of+them+were+retrospective+or+single-arm+prospective+studies.+In+this+study%2C+we+conducted+a+randomization+controlled+trial+to+explore+the+efficacy+of+additional+antihistamine+premedication+and+infusion+prolongation+in+prevention+of+oxaliplatin+induced+HSRs.+Oxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%3BOxaliplatin%2F+Hypersensitivity+reaction+%28HSR%29%2F+Prevention%22&lookfor=%22Prospective+Studies%22&type=Subject
PubPharm (2)
1
An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin. : An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
2
An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin. : An open-label randomized controlled trial to evaluate the efficacy of antihistamine premedication and infusion prolongation in prevention of hypersensitivity reaction to oxaliplatin.
enthalten in:
WHO International Clinical Trials Registry Platform
| 2023
Wird geladen...
1
[1]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Filter aufheben
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Ihre gewählten Filter
Filter bei nächster Suche beibehalten
Filter aufheben
Thema: Medical Condition: Hypersensitivity reaction (HSR) is a common toxicity associated with oxaliplatin. Oxaliplatin is a chemotherapy mainly used in gastrointestinal malignancies especially colorectal cancer. The incidences of oxaliplatin induced HSR vary from 12% to 25% (1-5) (6-8) (9, 10). Although it is usually mild to moderate severity (11), it could be severe (9, 10) and result in treatment discontinuation. Oxaliplatin induced HSR is a type I hypersensitivity. It usually occurs in later cycles of treatment course. In a common oxaliplatin based regimen, FOLFOX, it is more likely to firstly occur in seventh to ninth cycle of twelve-cycle treatment course.(12). Although many studies identified risk factors for HSRs, the most consistent risk factor is the number of oxaliplatin administered. (13-15) To date, there have been a few studies exploring preventive strategies for oxaliplatin induced HSRs. Most of them were retrospective or single-arm prospective studies. In this study, we conducted a randomization controlled trial to explore the efficacy of additional antihistamine premedication and infusion prolongation in prevention of oxaliplatin induced HSRs. Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention;Oxaliplatin/ Hypersensitivity reaction (HSR)/ Prevention
Medienart
2
Aufsätze
2
E-Artikel
2
E-Ressourcen
Zeitschriftentitel
2
WHO International Clinical Trials Registry Plat...
Thema
2
610
Medical Condition: Hypersensitivity reaction (H...
2
Phase: Phase 2
2
Recruitment Status: Completed
2
Study Type: Interventional
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
Erscheinungsjahr(e)
Von:
Bis:
Sprache
2
Englisch
Haven't found what you're looking for?
Wird geladen...